Science
Aakash Desai: TROP2 NMR as a Predictive Biomarker for Datopotamab Deruxtecan in NSCLC
Aakash Desai/LinkedIn

Aakash Desai: TROP2 NMR as a Predictive Biomarker for Datopotamab Deruxtecan in NSCLC

Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:

“TROP2 NMR : TROPION-Lung01 nsq NSCLC, no AGAs (n=221)

  • Dato-DXd, NMR+ vs NMR-: mPFS 7.2 vs 4.0 mo, HR 0.40
  • Docetaxel: 4.1 vs 4.4 mo, HR 0.94
  • Interaction P=0.0098.

How do we operationalize NMR?”

Title: Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Authors: Marina C. Garassino, Myung-Ju Ahn, Markus Schick, Ansh Kapil, Luis Paz-Ares, Aaron Lisberg, Melissa L. Johnson, Maurice Pérol, Toshio Shimizu, Rebecca Heist, Alexander Spira, Isamu Okamoto, Nicolas Girard, Robin Cornelissen, Elvire Pons-Tostivint, Min Hee Hong, Ricardo Zwirtes, Rachel Chiaverelli, Marlon Rebelatto, Matthew Sung, Chuyu Deng, James Harper, Danielle Carroll, Hadassah Sade, Jacob Sands.

Read the full article in Nature Medicine.

Aakash Desai: TROP2 NMR as a Predictive Biomarker for Datopotamab Deruxtecan in NSCLC

Continue exploring:

Dato-DXd in Lung Cancer: International Experts Define New Strategies to Manage ADC Toxicities
Aakash Desai: TROP2 NMR as a Predictive Biomarker for Datopotamab Deruxtecan in NSCLC

Aakash Desai Aaron Lisberg Alexander Spira Ansh Kapil Chuyu Deng Danielle Carroll Elvire Pons-Tostivint Hadassah Sade Isamu Okamoto Jacob Sands James Harper Luis Paz-Ares Lung cancer Marina C. Garassino Markus Schick Marlon Rebelatto Matthew Sung Maurice Pérol Melissa L. Johnson Min Hee Hong Myung-Ju Ahn Nature Medicine Nicolas Girard NSCLC Rachel Chiaverelli Rebecca Heist Ricardo Zwirtes Robin Cornelissen Toshio Shimizu TROP2